Bevacizumab is a recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody that binds and inhibits vascular endothelial growth factor (VEGF); blockade of VEGF signaling by bevacizumab inhibits angiogenesis and can lead to tumor stasis or necrosis [4, 5]. The gene discussed is VEGFA; the disease is neoplasm.